Novartis has announced disappointing results from its Phase III trial of serelaxin (RLX030) in patients with acute heart failure.
The primary endpoints of reduced cardiovascular death or worsening heart failure in patients with acute heart failure were not met in the study.
Shares in the pharmaceutical giant fell more than 2% to 72.95 Swiss francs at the opening bell on the Swiss Exchange this morning, before climbing back to 73.80.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze